Home/Pipeline/Cyclosporine A LNP Formulation

Cyclosporine A LNP Formulation

Inflammatory/Autoimmune conditions (Ophthalmology, Dermatology, etc.)

Pre-clinicalActive

Key Facts

Indication
Inflammatory/Autoimmune conditions (Ophthalmology, Dermatology, etc.)
Phase
Pre-clinical
Status
Active
Company

About Eyesiu Medicines

Eyesiu Medicines is a private, pre-clinical stage biotechnology company leveraging a patented lipid nanoparticle platform for drug delivery. Its core technology enables the formulation of lipophilic compounds like PEA and cyclosporine A into stable, solvent-free nanoparticles for rapid sublingual, topical, or systemic delivery. The company has launched its first nutraceutical product (PEArlboost spray and shampoo) to generate early revenue while advancing a therapeutic pipeline targeting neurology, ophthalmology, dermatology, and pulmonology. Eyesiu is currently raising public funding through its Eyevestor platform to finance further development.

View full company profile